Etanercept Biosimilars Pipeline: 15+ Innovators Pioneering Breakthrough Therapies | DelveInsight

The Etanercept market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Lupin, Intas Biopharmaceuticals, and Merck. These industry pioneers are transforming treatment strategies and redefining the future of Etanercept, bringing new hope to patients worldwide.

DelveInsight's "Etanercept - Biosimilar Insight, 2024" comprehensively analyzes the Etanercept market's current clinical landscape and growth prospects. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Etanercept drugs, the Etanercept pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Etanercept Pipeline Report
• DelveInsight's Etanercept Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline drugs for Etanercept treatment.
• The leading Etanercept companies include Sandoz, Lupin, Intas Biopharmaceuticals, Merck & Co. /Samsung Bioepis, AryoGen Pharmed, Rus Biopharm, Shanghai Celgen, and others are evaluating their lead assets to improve the Etanercept treatment landscape.
• Key Etanercept pipeline therapies in various stages of development include BX2922, CT-P05, SCB-808, PRX-106, SBDM-01, and others.
• In August 2023, STELARA (ustekinumab) and ENBREL (etanercept) were selected for Medicare price negotiation under the Inflation Reduction Act (IRA). These originator drugs, expected to face biosimilar competition in the coming years, were among the 10 initial medications chosen for pricing discussions.

Request a sample and discover the recent breakthroughs happening in the Etanercept pipeline landscape @ https://www.delveinsight.com/report-store/etanercept-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Etanercept Overview
Etanercept is prescribed for adults with moderately to severely active rheumatoid arthritis and for children aged four and older with chronic moderate to severe plaque psoriasis. It is also used to manage polyarticular idiopathic arthritis in patients aged two and older. Additionally, etanercept helps alleviate symptoms of psoriatic arthritis and ankylosing spondylitis.
This dimeric fusion protein comprises the extracellular ligand-binding portion of the human 75 kDa (p75) tumor necrosis factor receptor (TNFR) linked to the Fc region of human IgG1. The Fc component includes the CH2 and CH3 domains, along with the hinge region, but lacks the CH1 domain of IgG1. Produced using recombinant DNA technology in a Chinese hamster 0vary (CHO) mammalian cell expression system, etanercept consists of 934 amino acids. It is widely used to treat inflammatory conditions such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic polyarticular arthritis (JIA).

Find out more about Etanercept medication @ https://www.delveinsight.com/report-store/etanercept-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Etanercept Treatment Analysis: Drug Profile
GP2015: Sandoz
GP2015 is a biosimilar to etanercept, replicating the reference p75 TNF receptor-Fc fusion protein. Approved for all indications of its reference product, it is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, and pediatric plaque psoriasis. GP2015 exhibits similar physicochemical and pharmacodynamic properties to its reference drug, with demonstrated pharmacokinetic biosimilarity in healthy individuals. Clinical studies have shown that GP2015 provides equivalent efficacy in moderate-to-severe plaque psoriasis, with comparable safety, tolerability, and immunogenicity profiles to the original etanercept formulation.

Key Etanercept Therapies and Companies
• SBDM-01: Shilpa Biologicals

Learn more about the novel and emerging Etanercept pipeline therapies @ https://www.delveinsight.com/report-store/etanercept-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Etanercept Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Subcutaneous
• Intravenous

By Molecule Type
• Monoclonal antibodies
• Peptide
• Protein
• Small molecule

Scope of the Etanercept Pipeline Report
• Coverage: Global
• Key Etanercept Companies: Sandoz, Lupin, Intas Biopharmaceuticals, Merck & Co. /Samsung Bioepis, AryoGen Pharmed, Rus Biopharm, Shanghai Celgen, and others.
• Key Etanercept Pipeline Therapies: BX2922, CT-P05, SCB-808, PRX-106, SBDM-01, and others.

Dive deep into rich insights for drugs used for Etanercept treatment; visit @ https://www.delveinsight.com/report-store/etanercept-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Etanercept Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Etanercept Pipeline Therapeutics
6. Etanercept Pipeline: Late-Stage Products (Phase III)
7. Etanercept Pipeline: Late-Stage Products (Phase III)
8. Etanercept Pipeline: Mid-Stage Products (Phase II)
9. Etanercept Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.